Cargando…

Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas’ Inflammatory Bowel Disease Registry

BACKGROUND: To evaluate disease burden and patient-reported outcomes (PROs) of ulcerative colitis (UC) patients at enrollment into CorEvitas’ Inflammatory Bowel Disease Registry by therapy class. METHODS: Between May 3, 2017 and September 3, 2019, 773 UC registry patients were categorized by therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cross, Raymond K, Naegeli, April N, Harrison, Ryan W, Moore, Page C, Mackey, Rachel H, Crabtree, Margaux M, Lemay, Celeste A, Arora, Vipin, Morris, Nathan, Sontag, Angelina, Kayhan, Cem, Korzenik, Joshua R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802151/ https://www.ncbi.nlm.nih.gov/pubmed/36777423 http://dx.doi.org/10.1093/crocol/otac007

Ejemplares similares

Characteristics of Patients with Crohn’s Disease With or Without Perianal Fistulae in the CorEvitas Inflammatory Bowel Disease Registry
por: Fan, Yanni, et al.
Publicado: (2022)

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2022)

Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Skin Clearance is Associated with Reduced Treatment Failure in Patients with Psoriasis: Real-World Evidence from the CorEvitas Psoriasis Registry
por: McLean, Robert R., et al.
Publicado: (2023)

Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry
por: Walsh, Jessica A., et al.
Publicado: (2021)

The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry
por: Padula, Anthony S., et al.
Publicado: (2022)

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry
por: Yu, Chen, et al.
Publicado: (2022)

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry
por: McLean, Robert R., et al.
Publicado: (2023)

Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen‐B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2023)

Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry
por: Sebba, Anthony, et al.
Publicado: (2023)

Santa Evita /
por: Martínez, Tomás Eloy
Publicado: (1995)

Evita : imagenes de una pasion
Publicado: (1997)

EVITA: a tool for the early EValuation of pharmaceutical Innovations with regard to Therapeutic Advantage
por: Püntmann, Isabel, et al.
Publicado: (2010)

Left ventricular pseudoaneurysm after ascending, arch and descending aortic replacement with Evita Open Plus® prosthesis
por: Echevarría, JR, et al.
Publicado: (2013)

Effects of Vitamin D Supplementation on Renin and Aldosterone Concentrations in Patients with Advanced Heart Failure: The EVITA Trial
por: Zittermann, Armin, et al.
Publicado: (2018)

The EVITA framework for evidence-based mental health policy agenda setting in low- and middle-income countries
por: Votruba, Nicole, et al.
Publicado: (2020)

The role of diabetes in cardiomyopathies of different etiologies—Characteristics and 1-year follow-up results of the EVITA-HF registry
por: Meindl, Christine, et al.
Publicado: (2020)

Cor pulmonale in a case of infantile Gaucher's disease
por: Patra, Soumya, et al.
Publicado: (2011)

Rheumatoid interstitial lung disease presenting as cor pulmonale
por: Acharya, Sourya, et al.
Publicado: (2010)

Cor pulmonale /
por: Cruz Cruz, Juan
Publicado: (1987)

Cor Pulmonale
Publicado: (1953)

Method for cor alto and cor basse : complete English translation of the first edition published by Zetter, Paris, ca. 1824 : music reproduced in facsimile
por: Dauprat, Louis François, 1781-1868
Publicado: (1994)

Cor Triatriatum Sinistrum
por: Raheja, Hitesh, et al.
Publicado: (2018)

Cor triatriatum dexter
por: Zoltowska, Dominika, et al.
Publicado: (2018)

A 3 year post‐intervention follow‐up on mortality in advanced heart failure (EVITA vitamin D supplementation trial)
por: Zittermann, Armin, et al.
Publicado: (2020)

Cor Triatriatum Sinistrum: A rare disease with a common presentation
por: Al Sabri, Al Rumitha, et al.
Publicado: (2021)

Randomized supplementation of 4000 IU vitamin D(3) daily vs placebo on the prevalence of anemia in advanced heart failure: the EVITA trial
por: Ernst, J. B., et al.
Publicado: (2017)

Amor ... cor meu : suite coral
por: Querol Gavaldá, Miguel 1912-2002
Publicado: (1971)

The COR/COTR Answer Book
por: Boyd, Bob
Publicado: (2012)

Aur. Cor. Celsus on Medicine
Publicado: (1837)

Early and midterm results of frozen elephant trunk operation with Evita open stent-graft in patients with Marfan syndrome: results of a multicentre study
por: Widenka, Kazimierz Jan, et al.
Publicado: (2022)

Cor Pulmonale Secondary to Severe Pulmonary Hypertension As the First Manifestation of Graves' Disease
por: Santos, Sandra D, et al.
Publicado: (2022)

Immunoprofiling and immunoscoring in cor onary artery disease: From vascular research to the bedside?
por: Bruno, Antonino, et al.
Publicado: (2022)

Comparison Of Methods To Estimate Disease-Related Cost And Healthcare Resource Utilization For Autoimmune Diseases In Administrative Claims Databases
por: Schroeder, Krista M, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_521k5030sub01qu553a11ee0bo